Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid Analgesics-Reference-Cited by-同舟云学术

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid Analgesics

Published:2014 Issue:1 Volume:29 Page:29-43
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Zahari Zalina,Ismail Rusli

Publisher

Japanese Society for the Study of Xenobiotics

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference107 articles.

1. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I;Zhou;Clin. Pharmacokinet.,2009

2. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice;Gardiner;Pharmacol. Rev.,2006

3. Pharmacogenomic considerations in the opioid management of pain;Jannetto;Genome Med.,2010

4. Candidate gene polymorphisms predicting individual sensitivity to opioids;Kasai;Naunyn Schmiedebergs Arch. Pharmacol.,2008

5. Effect of genetic factors on opioid action;Kosarac;Curr. Opin. Anaesthesiol.,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach;Minerva Anestesiologica;2024-05

2. CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis;Pharmaceuticals;2023-07-03

3. Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study;International Journal of Molecular Sciences;2023-06-28

4. Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences;Frontiers in Pharmacology;2023-05-31

5. Détournement de médicaments à des fins toxicomaniaques;Bulletin de l'Académie Nationale de Médecine;2023-02